MRZM实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 03:03):

Stats
今日成交量	2 180.00
平均成交量	3 212.00
市值	4.43M
EPS	$0 ( 2024-03-24 )
下一个收益日期	( $0 ) 2024-05-15
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-21	Braeden Lichti	Sell	3 815 294	Common stock
2023-12-21	Braeden Lichti	Sell	2	10% Secured Convertible Promissory Note
2023-06-29	Lichti Braeden	Sell	106 327	Common shares
2023-07-07	Lichti Braeden	Sell	97 000	Common shares
2023-08-29	Lichti Braeden	Sell	105 000	Common shares

INSIDER POWER
-66.06
Last 78 transactions
Buy: 7 913 036 \| Sell: 10 266 700

Marizyme, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Marizyme, Inc. 财务报表

Annual	2022
营收:	$233 485
毛利润:	$179 166 (76.74 %)
EPS:	$-1.530

FY	2022
营收:	$233 485
毛利润:	$179 166 (76.74 %)
EPS:	$-1.530

FY	2021
营收:	$210 279
毛利润:	$129 925 (61.79 %)
EPS:	$-0.310

FY	2020
营收:	$197 136
毛利润:	$138 844 (70.43 %)
EPS:	$-0.220

Financial Reports:

No articles found.

Marizyme, Inc.

Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. Further, it is involved in developing MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease assessment. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.